Almeida DRP, Ruzicki J, Xu K, et al. - In the present study, the researchers sought to review the evidence and compare the effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD) and to build metrics to promote standardized comparison between different anti-VEGF agents within the Advanced VitreoRetinal Analytics (AVRA) model. The research examined key outcomes in clinical trials of bevacizumab, ranibizumab, aflibercept, and brolucizumab, including best corrected visual acuity (BCVA), number of injections, and duration of follow-up (minimum follow-up of 48 weeks). AVRA notes that a higher positive VRV (more letters gained per unit time), low InjMom (lower treatment burden requiring fewer interventions for a given visual acuity outcome), and VRA approximating zero (indicating stable vision over time) will be the ideal VEGF inhibitor for treating nAMD. In order to assess the optimal anti-VEGF agent for the treatment of nAMD, AVRA facilitates comparisons through different trials.